rulonilimab (F520)
/ Lunan Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 10
Of
10
Go to page
1
January 04, 2025
A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer
(clinicaltrials.gov)
- P2/3 | N=510 | Enrolling by invitation | Sponsor: Shandong New Time Pharmaceutical Co., LTD
New P2/3 trial • Cervical Cancer • Oncology • Solid Tumor
January 26, 2024
A Phase Ⅱ Study of F520 in Patients With Cervical Carcinoma
(clinicaltrials.gov)
- P2 | N=29 | Completed | Sponsor: Shandong New Time Pharmaceutical Co., LTD
Metastases • Monotherapy • New P2 trial • Cervical Cancer • Oncology • Solid Tumor
March 10, 2023
the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular Carcinoma
(clinicaltrials.gov)
- P2/3 | N=576 | Recruiting | Sponsor: Shandong New Time Pharmaceutical Co., LTD | Not yet recruiting ➔ Recruiting | Initiation date: Aug 2022 ➔ Nov 2022
Enrollment open • Trial initiation date • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor
February 22, 2023
Efficacy and Safety Study of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid Tumors
(clinicaltrials.gov)
- P1/2 | N=158 | Recruiting | Sponsor: Shandong New Time Pharmaceutical Co., LTD
Metastases • New P1/2 trial • Endometrial Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor
February 23, 2023
A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
(clinicaltrials.gov)
- P2 | N=84 | Not yet recruiting | Sponsor: Shandong New Time Pharmaceutical Co., LTD
Metastases • New P2 trial • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • EGFR • PD-L1 • ROS1
June 07, 2022
Phase Ⅱ/III Studies to Investigate the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib Compared to Placebo in Combination With Lenvatinib as First-Line Therapy in Subjects With Hepatocellular Carcinoma (HCC)
(clinicaltrials.gov)
- P2/3 | N=696 | Not yet recruiting | Sponsor: Shandong New Time Pharmaceutical Co., LTD
Combination therapy • New P2/3 trial • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor
January 05, 2022
A Phase II Study to Evaluate the Efficacy and Safety of F520 Combined With F007 in Patients With RR DLBCL
(clinicaltrials.gov)
- P2; N=62; Not yet recruiting; Sponsor: Shandong New Time Pharmaceutical Co., LTD
Clinical • New P2 trial • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20
November 19, 2020
A Phase Ⅱ Study of F520 in Patients With Urothelial Carcinoma
(clinicaltrials.gov)
- P2; N=80; Not yet recruiting; Sponsor: Shandong New Time Pharmaceutical Co., LTD
Clinical • New P2 trial • Oncology • Solid Tumor • Urothelial Cancer
October 22, 2020
A Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL)
(clinicaltrials.gov)
- P2; N=43; Not yet recruiting; Sponsor: Shandong New Time Pharmaceutical Co., LTD; Initiation date: Jul 2020 ➔ Nov 2020
Clinical • Trial initiation date • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • MRI
October 22, 2020
The Efficacy and Safety of F520 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma (PTCL).
(clinicaltrials.gov)
- P2; N=105; Not yet recruiting; Sponsor: Shandong New Time Pharmaceutical Co., LTD; Initiation date: Jul 2020 ➔ Nov 2020
Clinical • Trial initiation date • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • PD-L1
1 to 10
Of
10
Go to page
1